A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma

NCT03188042 | Completed Results FDA Device

• 1 other identifier: 16-02005
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This pilot study will test the preliminary efficacy and feasibility of an intervention protocol for one method of electric current stimulation, repetitive transorbital alternating current stimulation (rtACS), to treat visual impairment in people with glaucoma. We will evaluate a study protocol to use in future clinical trials to test the effectiveness of rtACS to ameliorate the progressive effects of vision loss both structurally and functionally in the eye, the visual pathway, and in regard to people's independence (i.e., functional ability). In this prospective, randomized controlled, double-masked pilot study, we will: 1) determine an effect of rtACS on ophthalmic structure and function (from retina to visual brain), 2) assess the methodology of procedures for assessment of people's functional ability and quality of life (QoL) to determine an effect of rtACS, and 3) assess the feasibility and implementation of the pilot study protocol for a larger multi-site, randomized controlled trial.

Conditions

Glaucoma

Keywords

Transorbital Alternating Current Stimulation; Glaucoma

Outcome Measures

Primary Outcomes (20)

• Change in Peripapillary RNFL Thickness

  Peripapillary retinal nerve fiber layer (RNFL) thickness (μm) measured using optical coherence tomography (OCT).

  Baseline, Week 4

• Change in Macular Ganglion Cell-Inner Plexiform Layer Thickness

  Macular ganglion cell-inner plexiform layer thickness (μm) measured using OCT.

  Baseline, Week 4

• Percentage Change in ON Head Cup-to-Disc Ratio

  Percentage change in optic nerve (ON) head cup-to-disc ratio measured using OCT.

  Baseline, Week 4

• Change in Humphrey Visual Field Analyzer Score

  The Humphrey Visual Field Analyzer assesses the mean deviation (dB), a measure of visual field sensitivity through threshold testing. dBs tested by the Humphrey analyzer range between 0 and 50 dB (0 is the brightest and 50 is the dimmest). A value of 0 means the patient could not see the brightest target, and a 50 means the dimmest target was seen. Most values are around 30 dB, and any numbers below this range imply a possible visual field defect.

  Baseline, Week 4

• Change in Score on Assessment of Life Habits (LIFE-H), Short Form 3.1

  The LIFE-H short form 3.1 is a 77-item questionnaire developed to measure: (1) how a respondent accomplishes regular activities and social roles and (2) respondent's satisfaction with how regular activities and social roles are accomplished. The LIFE-H total score is obtained by summing the scores on each item and then dividing by the number of items. The LIFE-H score ranges from 0 to 9, where a score of 0 indicates total handicap or total disruption in participation and a score of 9 means an optimal level of participation.

  Baseline, Week 4

• Change in Minnesota Low Vision Reading Test (MNRead): Reading Acuity Score

  An estimate of reading acuity is given by the smallest print size at which the patient can read the entire sentence without making significant errors. This method measures acuity to the nearest 0.1 logMAR. Each sentence in the MNRead Reading Acuity chart has 60 characters, which corresponds to 10 standard length words, assuming a standard word length of 6 characters (including a space). Reading acuity is calculated as follows: Reading acuity = size of smallest sentence read + 0.01 x number of errors.

  Baseline, Week 4

• Change in Score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)

  National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. The total score is the average of the domain scores.

  Baseline, Week 4

• Change in Score on 36-Item Short Form Survey (SF-36)

  The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state. The total score is the average of the domain scores.

  Baseline, Week 4

• VEP-Measured Amplitude (15% Contrast) at Baseline

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

  Baseline

• VEP-Measured Latency (15% Contrast) at Baseline

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

  Baseline

• VEP-Measured Amplitude (85% Contrast) at Baseline

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

  Baseline

• VEP-Measured Latency (85% Contrast) at Baseline

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

  Baseline

• VEP-Measured Amplitude (15% Contrast) at Week 4

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

  Week 4

• VEP-Measured Latency (15% Contrast) at Week 4

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

  Week 4

• VEP-Measured Amplitude (85% Contrast) at Week 4

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

  Week 4

• VEP-Measured Latency (85% Contrast) at Week 4

  Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

  Week 4

• Pelli-Robson Contrast Sensitivity Chart Score at Baseline

  The Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.

  Baseline

• Pelli-Robson Contrast Sensitivity Chart Score at Week 4

  The Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.

  Week 4

• Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Baseline

  ETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.

  Baseline

• Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Week 4

  ETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.

  Week 4

Study Arms (2)

rtACS Stimulation Group

EXPERIMENTAL

Device: rtACS Stimulation

Sham Intervention Group

SHAM COMPARATOR

Sham stimulation looks like rtACS, but is not active rtACS.

Device: Sham Intervention

Interventions

rtACS Stimulation DEVICE

Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.

rtACS Stimulation Group

Sham Intervention DEVICE

A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.

Sham Intervention Group

Eligibility Criteria

• Age: 50 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Live in a community, residential setting (i.e., non-institutionalized, not homeless)
• Diagnosis of glaucoma (not type-specific, excluding traumatic glaucoma): Moderate defect or worse in both eyes but not total blindness
• Visual field defects present for at least 6 months
• Best-corrected visual acuity of 20/200 (1.0 logMAR) or better in at least one eye
• Commitment to comply with study procedures (2 week period of intervention sessions) with baseline, post-intervention, and follow-up visits

You may not qualify if:

• Other optic comorbidity than glaucoma
• End-stage organ disease or medical condition with subsequent vision loss (e.g., diabetes, stroke)
• Other diseases of the retina or cataracts responsible for worse than 20/70 best-corrected visual acuity
• Photosensitivity to flickering lights
• Intraocular Pressure (IOP) \> 27 mmHg at baseline
• \* Medically diagnosed memory disorder or Telephone Interview for Cognitive Status-modified (TICS-m) score ≤ 27
• Electric or electronic implants (e.g., cardiac pacemaker)
• Metallic artifacts/implants in head and/or torso
• Diagnosed epilepsy
• Epileptic seizure within the past 3 years of enrollment date
• Auto-immune disease, acute stage (e.g., rheumatoid arthritis)
• Metastatic disease
• Certain mental diseases/psychiatric conditions (e.g., schizophrenia) that would preclude reliable testing and participation
• Unstable medical conditions (e.g., diabetes, diabetes causing diabetic retinopathy)
• Claustrophobia (to limit functional neuroimaging)

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

Related Publications (1)

• Ramos Cadena MLA, Sohn A, Livengood H, Lee TF, Rubin B, Hu J, Sabel BA, Matayev R, Panarelli J, Wollstein G, Schuman JS. Transorbital Alternating Current Stimulation in a Double-Masked Randomized Clinical Trial: Visual Functional Effect and Quality of Life. Ophthalmol Sci. 2024 Sep 4;5(1):100614. doi: 10.1016/j.xops.2024.100614. eCollection 2025 Jan-Feb.

  PMID: 39584183 DERIVED

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Results Point of Contact

• Title: Joel Schuman, MD, FACS
• Organization: NYU Langone Health

Joel.Schuman@nyu.edu

929-455-5030

Study Officials

• Joel Schuman, MD, FACS

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2017
• First Posted: June 15, 2017
• Study Start: December 14, 2017
• Primary Completion: October 20, 2022
• Study Completion: October 20, 2022
• Last Updated: February 9, 2024
• Results First Posted: February 9, 2024

Record last verified: 2024-02

Locations

US (1)